{Reference Type}: Journal Article
{Title}: Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022.
{Author}: Sandford R;Yadav R;Noble EK;Sumner K;Joshi D;Tartof SY;Wernli KJ;Martin ET;Gaglani M;Zimmerman RK;Talbot HK;Grijalva CG;Belongia EA;Carlson C;Coughlin M;Flannery B;Pearce B;Rogier E;
{Journal}: Influenza Other Respir Viruses
{Volume}: 18
{Issue}: 7
{Year}: 2024 Jul
{Factor}: 5.606
{DOI}: 10.1111/irv.13339
{Abstract}: We describe humoral immune responses in 105 ambulatory patients with laboratory-confirmed SARS-CoV-2 Omicron variant infection. In dried blood spot (DBS) collected within 5 days of illness onset and during convalescence, we measured binding antibody (bAb) against ancestral spike protein receptor binding domain (RBD) and nucleocapsid (N) protein using a commercial multiplex bead assay. Geometric mean bAb concentrations against RBD increased by a factor of 2.5 from 1258 to 3189 units/mL and by a factor of 47 against N protein from 5.5 to 259 units/mL between acute illness and convalescence; lower concentrations were associated with greater geometric mean ratios. Paired DBS specimens may be used to evaluate humoral response to SARS-CoV-2 infection.